PE20001467A1 - Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina - Google Patents
Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquininaInfo
- Publication number
- PE20001467A1 PE20001467A1 PE2000000125A PE0001252000A PE20001467A1 PE 20001467 A1 PE20001467 A1 PE 20001467A1 PE 2000000125 A PE2000000125 A PE 2000000125A PE 0001252000 A PE0001252000 A PE 0001252000A PE 20001467 A1 PE20001467 A1 PE 20001467A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- phenylpyridine
- derivatives
- alcoxy
- trifluoromethyl
- Prior art date
Links
- 150000005362 4-phenylpyridines Chemical class 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- JKHCSKNIYWXLNC-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-n-methylpyridine-3-carboxamide Chemical compound C=1N=CC=C(C=2C(=CC=CC=2)Cl)C=1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JKHCSKNIYWXLNC-UHFFFAOYSA-N 0.000 abstract 1
- 229960003966 nicotinamide Drugs 0.000 abstract 1
- 239000011570 nicotinamide Substances 0.000 abstract 1
- 150000003512 tertiary amines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99103504 | 1999-02-24 | ||
EP99123689 | 1999-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20001467A1 true PE20001467A1 (es) | 2000-12-20 |
Family
ID=26152908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2000000125A PE20001467A1 (es) | 1999-02-24 | 2000-02-18 | Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina |
Country Status (54)
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3979099A (en) * | 1998-05-11 | 1999-11-29 | Philadelphia Health & Education Corporation | (mct-1), a human oncogene |
PL350427A1 (en) * | 1999-02-24 | 2002-12-16 | Hoffmann La Roche | Phenylâ and pyridinyl derivatives as neurokinin 1 antagonists |
US6291465B1 (en) * | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
ES2208205T3 (es) * | 1999-11-29 | 2004-06-16 | F. Hoffmann-La Roche Ag | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida. |
US6303790B1 (en) | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
JP3938651B2 (ja) * | 2000-04-13 | 2007-06-27 | ă»ăłăă©ă«çĄćæ ȘćŒäŒç€Ÿ | ć ćŠæŽ»æ§Î±âăĄăă«âăăčâïŒăïŒâïŒăăȘăă«ăȘăăĄăă«ïŒăăłăžă«ăąăăłăźèŁœé æčæł |
DK1303490T3 (da) * | 2000-07-14 | 2008-08-25 | Hoffmann La Roche | N-oxider som NK1-receptorantagoniskprodugs af 4-phenyl-pyridinderivater |
TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
MXPA03005169A (es) | 2000-12-14 | 2003-09-22 | Hoffmann La Roche | Matriz lipidica auto-emulsificante. |
US6531597B2 (en) * | 2001-02-13 | 2003-03-11 | Hoffmann-La Roche Inc. | Process for preparation of 2-phenyl acetic acid derivatives |
US7112593B2 (en) | 2001-03-27 | 2006-09-26 | Eisai Co., Ltd. | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient |
BR0209151A (pt) * | 2001-04-23 | 2004-07-13 | Hoffmann La Roche | Uso de antagonistas de receptor nk-1 contra hiperplasia prostĂĄtica benigna |
ATE491474T1 (de) * | 2001-06-07 | 2011-01-15 | Sang Christine Dr | Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
CA2457250C (en) * | 2001-09-10 | 2010-03-30 | F. Hoffmann-La Roche Ag | Oily thixotropic formulations |
US7390813B1 (en) | 2001-12-21 | 2008-06-24 | Xenon Pharmaceuticals Inc. | Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents |
BR0314126A (pt) | 2002-09-20 | 2005-06-28 | Pfizer Prod Inc | Ligandos de amida acĂŹclica e sulfonamida para o receptor de estrogĂȘnio |
CA2508165C (en) | 2002-12-06 | 2014-05-06 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
US8729107B2 (en) * | 2002-12-06 | 2014-05-20 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
KR100700421B1 (ko) * | 2003-01-31 | 2007-03-28 | ìí. ížíë§-ëŒ ëĄì ìêČ | 2-(3,5-ëčì€-ížëŒìŽí룚ì€ëĄë©íž-íë)-ïŒź-[6-(1,1-ë€ìŽì„ì-1λ6-í°ì€ëȘšíŽëа-4-ìŒ)-4-(4-í룚ì€ëĄ-2-ë©íž-íë)-íŒëŠŹë-3-ìŒ]-ïŒź-ë©íž-ììŽìë¶í°ë„Žì믞ëì ìëĄìŽ êȰì ëłíìČŽ |
DE602004008631T2 (de) | 2003-07-03 | 2008-07-10 | F. Hoffmann-La Roche Ag | Duale nk1/nk3 antagonisten zur behandlung von schizophrenie |
US7288658B2 (en) | 2003-07-15 | 2007-10-30 | Hoffmann-La Roche Inc. | Process for preparation of pyridine derivatives |
WO2005011655A2 (en) | 2003-07-30 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
KR100881240B1 (ko) * | 2004-07-06 | 2009-02-05 | ìí. ížíë§-ëŒ ëĄì ìêČ | ïŒźïœ-1 ìì©ìČŽ êžžíì ì í©ì±ì ììŽì ì€ê°ìČŽëĄììŹì©ëë ìčŽë„Žëł”ì€ì믞ë íŒëŠŹë ì ëìČŽì ì ìĄ° ë°©ëČ |
JP2008505891A (ja) * | 2004-07-06 | 2008-02-28 | ăŒăăłă»ăăĄăŒăă·ă„ăŒăăŁă«ă«ășă»ă€ăłăłăŒăăŹă€ăăă | æČ»çèŹăšăăŠăźăăłăăłăąăăèȘć°äœăăăłăăăăźäœżçš |
EP1776342B1 (en) | 2004-07-06 | 2011-03-02 | F. Hoffmann-La Roche AG | Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists |
US20060030556A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency |
WO2006013205A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
JP4958786B2 (ja) | 2004-09-20 | 2012-06-20 | ăŒăăłă»ăăĄăŒăă·ă„ăŒăăŁă«ă«ășă»ă€ăłăłăŒăăŹă€ăăă | è€çŽ ç°èȘć°äœăăăłæČ»çèŹăšăăŠăźăăăăźäœżçš |
EP1814551A2 (en) | 2004-09-20 | 2007-08-08 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
WO2006034279A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
JP4958785B2 (ja) | 2004-09-20 | 2012-06-20 | ăŒăăłă»ăăĄăŒăă·ă„ăŒăăŁă«ă«ășă»ă€ăłăłăŒăăŹă€ăăă | è€çŽ ç°èȘć°äœăăăłăčăăąăă€ă«âïŒŁïœïŒĄăă”ăă„ă©ăŒăŒă€ăłăăăżăŒăšăăŠăźăăăăźäœżçš |
CA2580844A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase |
AU2005286648A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
CA2580787A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
US7569725B2 (en) * | 2004-10-21 | 2009-08-04 | Britsol-Myers Squibb Company | Anthranilic acid derivatives as inhibitors of 17ÎČ-hydroxysteroid dehydrogenase 3 |
US20060135636A1 (en) * | 2004-11-15 | 2006-06-22 | Honeywell International Inc. | Isocyanate-based polymer foams with nano-scale materials |
ES2329827T3 (es) * | 2005-02-22 | 2009-12-01 | F. Hoffmann-La Roche Ag | Antagonistas de nk1. |
CN101128428A (zh) * | 2005-02-24 | 2008-02-20 | è©čæŁźèŻäžæéć Źćž | äœäžșéŸçŠ»ćééæćŒćçæ°çćĄć¶èĄçç© |
EP2281556A1 (en) | 2005-02-25 | 2011-02-09 | F. Hoffmann-La Roche AG | Tablets with improved drugs substance dispersibility |
CA2602445C (en) * | 2005-03-23 | 2013-08-20 | F.Hoffmann-La Roche Ag | Metabolites for nk-i antagonists for emesis |
AU2006343359A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
JP5143738B2 (ja) * | 2005-08-11 | 2013-02-13 | ăăŒăăăŻăč ăăĄăŒăă·ă„ăŒăăŁă«ă«ăș ă€ăłăłăŒăăŹă€ăăă | ćąèæ§ç·ç¶çèăłăłăăŻăżăłăčć¶ćŸĄć ćăźèȘżçŻç©èłȘ |
AR058805A1 (es) | 2005-09-09 | 2008-02-27 | Smithkline Beecham Corp | Derivados biciclicos de piridina utiles como agentes antipsicoticos |
MY143784A (en) * | 2005-09-23 | 2011-07-15 | Hoffmann La Roche | Novel dosage formulation |
KR20130034062A (ko) | 2005-11-08 | 2013-04-04 | ëČí ì€ íë§ìí°ìčŒì€ ìžìœíŹë ìŽí°ë | ïŒĄïœïœ êČ°í© ìčŽìžíž ììĄìČŽì í€í ëĄìŹìŽíŽëŠ ìĄ°ì ì |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US7872022B2 (en) * | 2006-04-03 | 2011-01-18 | Hoffmann-La Roche Inc. | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety |
PT2674428T (pt) | 2006-04-07 | 2016-07-14 | Vertex Pharma | Modeladores de transportadores de cassetes de ligação de atp |
USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US7754739B2 (en) * | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
AU2008251504B2 (en) | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
LT3170818T (lt) | 2007-12-07 | 2020-05-25 | Vertex Pharmaceuticals Incorporated | Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinÄs rĆ«gĆĄties formos |
ES2406940T3 (es) * | 2007-12-07 | 2013-06-10 | Vertex Pharmaceuticals Incorporated | Procedimientos para producir ĂĄcidos cicloalquilcarboxiamido-piridinabenzoicos |
JP2011512413A (ja) * | 2008-02-19 | 2011-04-21 | ă°ă©ăŻăœăčăăčăŻă©ă€ăłă»ăȘăăăăă»ă©ă€ăąăăȘăăŁă»ă«ăłăăăŒ | ïœïœăźé»ćźłć€ăšăăŠăźăąăăȘăăăȘăžăł |
CA2716109C (en) | 2008-02-28 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
GB0814340D0 (en) * | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
ES2440938T3 (es) * | 2009-08-27 | 2014-01-31 | Nerre Therapeutics Limited | Formas anhidrato de un derivado de piridina |
PE20121483A1 (es) | 2009-11-18 | 2012-12-02 | Helsinn Healthcare Sa | Composiciones para tratar nausea y vomito centralmente mediados |
EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
TW201143768A (en) * | 2009-12-15 | 2011-12-16 | Lundbeck & Co As H | Pyridone derivatives as NK3 antagonists |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
MX379946B (es) | 2010-04-07 | 2025-03-11 | Vertex Pharma | Composiciones farmacéuticas de åcido 3-(6-(1-(2,2 difluorobenzo[d][1,3]dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico y su administración. |
AR081069A1 (es) | 2010-04-07 | 2012-06-06 | Vertex Pharma | Formas solidas del acido 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico |
ES2858351T3 (es) | 2010-04-22 | 2021-09-30 | Vertex Pharma | Compuesto intermedio para proceso de producciĂłn de compuestos de cicloalquilcaraboxamido-indol |
EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
US20140256740A1 (en) * | 2011-07-29 | 2014-09-11 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
EP2736329A4 (en) * | 2011-07-29 | 2015-03-25 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
ES2579616T3 (es) | 2011-10-18 | 2016-08-12 | Helsinn Healthcare Sa | Combinaciones terapéuticas de netupitant y palonosetrón |
EP2776427B1 (en) | 2011-11-08 | 2017-02-01 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
HK1209318A1 (en) | 2012-07-16 | 2016-04-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
WO2015068744A1 (ja) * | 2013-11-08 | 2015-05-14 | ăăă»ă€èŹćć·„æ„æ ȘćŒäŒç€Ÿ | ă«ă«ăăă·ăĄăă«ăăăȘăžăłèȘć°äœ |
PL3068392T3 (pl) | 2013-11-12 | 2021-07-19 | Vertex Pharmaceuticals Incorporated | Proces wytwarzania kompozycji farmaceutycznych do leczenia chorĂłb, w ktĂłrych poĆredniczy cftr |
HUE055369T2 (hu) | 2014-04-15 | 2021-11-29 | Vertex Pharma | GyĂłgyĂĄszati kĂ©szĂtmĂ©nyek cisztĂĄs fibrĂłzis transzmembrĂĄn konduktancia regulĂĄtor kövzetĂtette betegsĂ©gek kezelĂ©sĂ©re |
US20150315149A1 (en) * | 2014-05-05 | 2015-11-05 | Apicore Us Llc | Methods of making netupitant and intermediates thereof |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | æ„ćæ©çè„ćć·„æ„èĄä»œæéć Źćž | Cyclohexylpyridine derivative |
TW201613888A (en) * | 2014-09-26 | 2016-04-16 | Helsinn Healthcare Sa | Crystalline forms of an NK-1 antagonist |
JP6494757B2 (ja) | 2014-11-18 | 2019-04-03 | ăăŒăăăŻăč ăăĄăŒăă·ă„ăŒăăŁă«ă«ăș ă€ăłăłăŒăăŹă€ăăăïŒ¶ïœ ïœïœïœ ïœ ïŒ°ïœïœïœïœïœïœïœ ïœïœïœïœïœïœïœ ïœïœïœïœïœïœïœïœïœïœ ïœ | ăă€ăčă«ăŒăăă詊éšé«éæ¶ČäœăŻăăăă°ă©ăăŁăŒăèĄăăăă»ăč |
AU2016226006B2 (en) | 2015-03-04 | 2021-03-04 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
CN105061303A (zh) * | 2015-08-03 | 2015-11-18 | æéœæŹŁæ·é«æ°ææŻćŒćæéć Źćž | äžç§ć¶ć€ć„抄ćĄćŠć łéźäžéŽäœn-çČćș-4-(2-çČćșèŻćș)-6-(4-çČćș-1-ććȘćș)-3-ćĄć¶èșçæ°æčæł |
EP4019018A1 (en) | 2015-09-11 | 2022-06-29 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
CN108368062A (zh) * | 2015-12-07 | 2018-08-03 | æ©çèŻćć·„äžæ ȘćŒäŒç€Ÿ | Nk1ćäœæźæć |
US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
TW202246215A (zh) * | 2015-12-18 | 2022-12-01 | çŸćäșćŸ·ć©ć æŻć Źćž | äœçșéć šèș«ïœïœïœïŒäżæćäčç¶ć代äčïŒïŒèŻćșćĄć¶ććç© |
CN106892864A (zh) * | 2015-12-21 | 2017-06-27 | äžæ”·ç§èèŻç©ç ćæéć Źćž | äžç§ć„抄çźćŠæžžçŠ»çą±çæ¶ćaćć ¶ć¶ć€æčæł |
CN115531553A (zh) | 2015-12-22 | 2022-12-30 | æŠç°èŻćć·„äžæ ȘćŒäŒç€Ÿ | ć äœgèçœ-ć¶èçćäœçäžéšćè°èć |
IL312486B2 (en) | 2017-04-10 | 2025-05-01 | Chase Therapeutics Corp | NK1 antagonist combination and method for treating synucleinopathies |
KR20250069704A (ko) | 2017-06-30 | 2025-05-19 | ìČŽìŽì€ í ëŒíší±ì€ ìœíŹë ìŽì | ì°ìžìŠì ìčëŁíêž° ìí nk-1 êžžíì ìĄ°ì±ëŹŒ ë° ì°ìžìŠ ìčëŁì ìŹì©íë ë°©ëČ |
CN109384712B (zh) * | 2017-08-14 | 2021-05-07 | ćäșŹćźœćć»èŻç§ææéć Źćž | é¶ćnk1ćäœæźæććć ¶ćšćçæèŽæ¶ćżăććæČ»çäžçćșçš |
EP3672964A4 (en) | 2017-08-21 | 2021-05-26 | Leiutis Pharmaceuticals Pvt. Ltd. | Novel triple combination formulations for antiemetic therapy |
US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
MX2020008456A (es) * | 2018-09-28 | 2020-09-25 | Vanda Pharmaceuticals Inc | Uso de tradipitant para tratar la cinetosis. |
WO2020132716A1 (en) * | 2018-12-24 | 2020-07-02 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Chemical compound manufacture, new salt form, and therapeutic uses thereof |
CN112174881B (zh) * | 2019-07-04 | 2022-06-21 | äžæ”·æŁźèŸć»èŻæéć Źćž | äžç§ć„抄ćčćŠçèĄçç©ćć ¶ć¶ć€æčæł |
KR20220050956A (ko) * | 2019-08-23 | 2022-04-25 | ì ì€ížëëŠŹì€ íë§ìí°ìčŒì€ 늏믞í°ë (ížë ìŽë© ì ìŠ íë ì€ìëŒ ëŽëĄ) | ìčëŁ ë°©ëČ ë° ìŽì ì©ë |
KR20220165251A (ko) | 2020-04-03 | 2022-12-14 | ë€ë„Ž ìëŒíší±ì€ 늏믞í°ë | íšíìŠ, íšíì± ìŒíŹ, êžì± ížíĄ êł€ë ìŠíê”° (ards) ëë ë€ë°ì± êž°êŽ êž°ë„ì„ì ìŠíê”° (mods)ìŒëĄë¶í° ì íë ì§íì ìčëŁíêž° ìí nk-1 ìì©ìČŽ êžžíì |
US11872222B2 (en) | 2020-06-02 | 2024-01-16 | Nerre Therapeutics Limited | Uses |
US12097197B2 (en) | 2021-12-21 | 2024-09-24 | Slayback Pharma Llc | Stable liquid compositions of netupitant and palonosetron |
EP4385500A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Fixed dose combination comprising netupitant and palonosetron |
EP4385497A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
KR20250125376A (ko) | 2022-12-12 | 2025-08-21 | ìíë ë ìŽ. í°íë°íìŽ êČì ëČ í ìŽíž ïŒ ìœ. ìčŽêČ | ë€íŹíŒííž ë° íëĄë žìžížëĄ ì íŹíšíë êł ì ì©ë ëł”í©ì |
WO2024126408A1 (en) | 2022-12-12 | 2024-06-20 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1557420A (en) | 1977-03-10 | 1979-12-12 | Soc D Etudes Prod Chimique | Preparation of isobutyramide derivatives |
KR810001320B1 (ko) | 1977-03-17 | 1981-10-14 | ìì넎 ìëž | ì ê·í ìŽìë¶í°ëŒëŻžëë„ì ì ìĄ°ë°©ëČ |
KR810001697B1 (ko) | 1978-02-06 | 1981-10-27 | ìì넎 ìëž | ìŽìë¶í°ëŒëŻžë ì ëìČŽì ì ê·í ì ìĄ°ë°©ëČ |
EP0089765A3 (en) | 1982-03-17 | 1984-05-23 | Smith Kline & French Laboratories Limited | Pyridine derivatives |
US4745123A (en) * | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
GB8607313D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Pharmaceutical compositions |
GB8607312D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
CA1339423C (en) | 1988-09-14 | 1997-09-02 | Yuji Ono | Pyridine compounds and pharmaceutical use thereof |
US4994456A (en) | 1989-03-01 | 1991-02-19 | Nisshin Flour Milling Co., Ltd. | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same |
US4973597A (en) | 1989-06-30 | 1990-11-27 | Eli Lilly And Company | Anticonvulsant agents |
HU207047B (en) | 1989-11-07 | 1993-03-01 | Richter Gedeon Vegyeszet | Process for producing new pyridine derivatives and pharmaceutical copositions comprising same |
US5364943A (en) | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
GB9021056D0 (en) | 1990-09-27 | 1990-11-07 | Pfizer Ltd | Antiarrhythmic agents |
GB9214120D0 (en) | 1991-07-25 | 1992-08-12 | Ici Plc | Therapeutic amides |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
WO1994003429A1 (en) | 1992-07-31 | 1994-02-17 | Merck Sharp & Dohme Limited | Substituted amines as tachykinin receptor antagonists |
US5387595A (en) | 1992-08-26 | 1995-02-07 | Merck & Co., Inc. | Alicyclic compounds as tachykinin receptor antagonists |
GB9305672D0 (en) | 1993-03-19 | 1993-05-05 | Wyeth John & Brother Ltd | Amide derivatives |
NZ264063A (en) | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
CZ288176B6 (en) | 1993-12-29 | 2001-05-16 | Merck Sharp & Dohme | Substituted morpholine derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical preparations in which they are comprised |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
AU693898B2 (en) | 1994-06-06 | 1998-07-09 | Warner-Lambert Company | Tachykinin (NK1) receptor antagonists |
US6294537B1 (en) | 1995-03-17 | 2001-09-25 | Sanofi-Synthelabo | Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools |
NO309272B1 (no) * | 1995-03-24 | 2001-01-08 | Takeda Chemical Industries Ltd | Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene |
AR004735A1 (es) * | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
ES2214604T3 (es) | 1996-03-29 | 2004-09-16 | Pfizer Inc. | Derivados de la 6-fenilpiridil-2-amina. |
AU4885097A (en) | 1996-11-08 | 1998-06-03 | Sankyo Company Limited | Arylureas or arylmethylcarbamoyl derivatives |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
PL350427A1 (en) * | 1999-02-24 | 2002-12-16 | Hoffmann La Roche | Phenylâ and pyridinyl derivatives as neurokinin 1 antagonists |
US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
ES2208205T3 (es) * | 1999-11-29 | 2004-06-16 | F. Hoffmann-La Roche Ag | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida. |
-
2000
- 2000-02-15 EP EP03026298A patent/EP1394150B1/en not_active Expired - Lifetime
- 2000-02-15 DE DE60014216T patent/DE60014216T2/de not_active Expired - Lifetime
- 2000-02-15 SE SE00102260T patent/SE1035115T5/xx unknown
- 2000-02-15 ES ES00102260T patent/ES2226622T3/es not_active Expired - Lifetime
- 2000-02-15 PT PT00102260T patent/PT1035115E/pt unknown
- 2000-02-15 AT AT03026298T patent/ATE496032T1/de active
- 2000-02-15 SI SI200030506T patent/SI1035115T1/xx unknown
- 2000-02-15 DE DE60045564T patent/DE60045564D1/de not_active Expired - Lifetime
- 2000-02-15 DK DK00102260T patent/DK1035115T3/da active
- 2000-02-15 AT AT00102260T patent/ATE277905T1/de active
- 2000-02-15 EP EP00102260A patent/EP1035115B1/en not_active Expired - Lifetime
- 2000-02-15 PT PT03026298T patent/PT1394150E/pt unknown
- 2000-02-15 DK DK03026298.4T patent/DK1394150T3/da active
- 2000-02-15 ES ES03026298T patent/ES2359235T3/es not_active Expired - Lifetime
- 2000-02-18 NZ NZ502948A patent/NZ502948A/en not_active IP Right Cessation
- 2000-02-18 GB GB0003908A patent/GB2347422A/en not_active Withdrawn
- 2000-02-18 PE PE2000000125A patent/PE20001467A1/es not_active IP Right Cessation
- 2000-02-21 IL IL134654A patent/IL134654A/en active Protection Beyond IP Right Term
- 2000-02-21 CZ CZ20000609A patent/CZ300596B6/cs not_active IP Right Cessation
- 2000-02-21 HU HU0000748A patent/HU227629B1/hu unknown
- 2000-02-21 GE GEAP20005227A patent/GEP20022676B/en unknown
- 2000-02-22 SK SK235-2000A patent/SK287911B6/sk not_active IP Right Cessation
- 2000-02-22 MY MYPI20000648A patent/MY123648A/en unknown
- 2000-02-22 DE DE10008042A patent/DE10008042A1/de not_active Withdrawn
- 2000-02-22 RS YUP-95/00A patent/RS50194B/sr unknown
- 2000-02-22 UA UA2000021039A patent/UA71547C2/uk unknown
- 2000-02-22 IS IS5381A patent/IS2116B/is unknown
- 2000-02-22 TN TNTNSN00032A patent/TNSN00032A1/fr unknown
- 2000-02-22 PA PA20008491101A patent/PA8491101A1/es unknown
- 2000-02-22 AR ARP000100737A patent/AR029614A1/es active IP Right Grant
- 2000-02-22 RS RS20080562A patent/RS53869B1/en unknown
- 2000-02-22 RS RSP-2008/0562A patent/RS20080562A/sr unknown
- 2000-02-22 SK SK5052-2008A patent/SK287912B6/sk not_active IP Right Cessation
- 2000-02-22 MY MYPI20044751A patent/MY147451A/en unknown
- 2000-02-22 US US09/507,456 patent/US6297375B1/en not_active Expired - Lifetime
- 2000-02-22 EG EG20000206A patent/EG23817A/xx active
- 2000-02-22 JO JO200014A patent/JO2294B1/en active
- 2000-02-22 ME MEP-2009-57A patent/ME00593B/me unknown
- 2000-02-22 FR FR0002170A patent/FR2790473B1/fr not_active Expired - Fee Related
- 2000-02-22 GT GT200000017A patent/GT200000017A/es unknown
- 2000-02-23 EA EA200000155A patent/EA003673B1/ru active Protection Beyond IP Right Term
- 2000-02-23 NO NO20000885A patent/NO315554B1/no not_active IP Right Cessation
- 2000-02-23 ES ES200000418A patent/ES2171109B2/es not_active Expired - Fee Related
- 2000-02-23 CA CA2299139A patent/CA2299139C/en not_active Expired - Lifetime
- 2000-02-23 SV SV2000000024A patent/SV2002000024A/es active IP Right Grant
- 2000-02-23 BR BRPI0000908A patent/BRPI0000908B8/pt not_active IP Right Cessation
- 2000-02-23 ZA ZA200000894A patent/ZA200000894B/xx unknown
- 2000-02-23 IT IT2000MI000328A patent/IT1320763B1/it active
- 2000-02-23 CN CNB001024019A patent/CN1142144C/zh not_active Expired - Lifetime
- 2000-02-23 SG SG200001033A patent/SG91856A1/en unknown
- 2000-02-23 KR KR10-2000-0008674A patent/KR100384904B1/ko not_active Expired - Lifetime
- 2000-02-23 HR HR20000097A patent/HRP20000097B1/xx not_active IP Right Cessation
- 2000-02-23 MA MA25913A patent/MA26722A1/fr unknown
- 2000-02-24 BG BG104187A patent/BG64554B1/bg unknown
- 2000-02-24 OA OA1200000052A patent/OA11680A/fr unknown
- 2000-02-24 TR TR2000/00520A patent/TR200000520A3/tr unknown
- 2000-02-24 PL PL338598A patent/PL217311B1/pl unknown
- 2000-02-24 JP JP2000047003A patent/JP3399900B2/ja not_active Expired - Lifetime
- 2000-02-24 AU AU19468/00A patent/AU767048B2/en not_active Expired
- 2000-02-25 TW TW089103387A patent/TWI288746B/zh not_active IP Right Cessation
-
2001
- 2001-07-10 US US09/901,982 patent/US6479483B2/en not_active Expired - Lifetime
-
2007
- 2007-09-24 AR ARP070104196A patent/AR062949A2/es active IP Right Grant
-
2008
- 2008-06-27 HR HRP20080306AA patent/HRP20080306B1/hr not_active IP Right Cessation
-
2009
- 2009-12-10 UY UY0001032314A patent/UY32314A/es not_active Application Discontinuation
-
2011
- 2011-02-10 CY CY20111100162T patent/CY1111317T1/el unknown
-
2015
- 2015-06-17 LU LU92745C patent/LU92745I2/xx unknown
- 2015-07-08 FR FR15C0049C patent/FR15C0049I2/fr active Active
- 2015-08-28 NL NL300758C patent/NL300758I1/nl unknown
- 2015-10-21 LT LTPA2015036C patent/LTC1035115I2/lt unknown
- 2015-10-29 BE BE2015C057C patent/BE2015C057I2/fr unknown
- 2015-10-29 CY CY2015042C patent/CY2015042I1/el unknown
- 2015-10-29 CY CY2015041C patent/CY2015041I1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20001467A1 (es) | Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina | |
PE20010009A1 (es) | Derivados de fenil - y piridinilo como antagonistas del receptor de la neuroquinina 1 | |
PE20050482A1 (es) | Derivados de dihidrobenzofuranilo alcanamida | |
PE20020258A1 (es) | Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1) | |
PE20030238A1 (es) | Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales | |
PE20020721A1 (es) | Derivados de quinuclidina como agentes antimuscarinicos m3 | |
UY27029A1 (es) | Nuevos derivados de pirazolpiridina sustituidos con piridina | |
DE69120100D1 (de) | Annelierte Thiophen-Derivate, ihre Herstellung und Verwendung | |
PE20001551A1 (es) | Derivados de eter biarilico como inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc | |
NO20053960L (no) | Piperidin-benzensulfonamidderivater | |
BR0306208A (pt) | Compostos de dibenzilamina e seu uso farmacĂȘutico | |
PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
PE106499A1 (es) | Antagonistas del receptor ccr-3 | |
AR029616A1 (es) | Compuestos derivados de 3-fenil-piridina, su uso, un proceso para prepararlos y medicamentos que los contienen | |
AR058618A1 (es) | "( indazol -5- il) - pirazinas y (1,3- dihidro- indol-2- ona) - pirazinas para el tratamiento de enfermedades y afecciones mediadas por rho quinasa | |
PE20000170A1 (es) | Derivados benzosulfonas | |
PE20020657A1 (es) | Derivados de amida de piperidinas 1,4-disustituidas de formula (i) | |
PE20050465A1 (es) | Compuestos derivados de quinuclidina como antagonistas del receptor muscarinico m3 | |
ES2113081T3 (es) | 1,4-benzotiazepinas utiles como agentes neurologicos. | |
PE20040772A1 (es) | Composicion y actividad antiviral de derivados de piperazina azaindoloxoaceticos | |
ATE377602T1 (de) | Morphinanderivate und ihre medizinische anwendung | |
PE20030761A1 (es) | Derivados del 7-amino-benzotiazol | |
PE20040757A1 (es) | Derivados de benzoxazina | |
ES2154605B1 (es) | Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3 | |
JO2235B1 (en) | Derivatives of phenyl |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
MK | Expiration of term |